Complement-mediated tumor-specific cell lysis by antibody combinations targeting epidermal growth factor receptor (EGFR) and its variant III (EGFRvIII)
スポンサーリンク
概要
- 論文の詳細を見る
- 2011-10-10
著者
-
Berger Sven
Section For Stem Cell Transplantation And Immunotherapy Christian-albrechts-university And Universit
-
Lohse Stefan
Department Of Medicine Ii And Iv Christian-albrechts-university And University Hospital Schleswig-ho
-
Klausz Katja
Section For Stem Cell Transplantation And Immunotherapy Christian-albrechts-university And Universit
-
Peipp Matthias
Section For Stem Cell Transplantation And Immunotherapy Christian-albrechts-university And Universit
-
Derer Stefanie
Section For Stem Cell Transplantation And Immunotherapy Christian-albrechts-university And Universit
-
Valerius Thomas
Section For Stem Cell Transplantation And Immunotherapy Christian-albrechts-university And Universit
-
Dechant Michael
Department Of Medicine Ii And Iv Christian-albrechts-university And University Hospital Schleswig-ho
-
VAN BUEREN
Genmab BV
-
LOHSE Stefan
Section for Stem Cell Transplantation and Immunotherapy, Department of Internal Medicine II, University Hospital Schleswig-Holstein and Christian-Albrechts-University
-
VAN DE
Genmab BV
-
PARREN Paul
Genmab BV
-
Dechant Michael
Department Of Internal Medicine Iv University Hospital Schleswig-holstein And Christian-albrechts-university
-
Lohse Stefan
Section For Stem Cell Transplantation And Immunotherapy Department Of Internal Medicine Ii University Hospital Schleswig-holstein And Christian-albrechts-university
関連論文
- Fc-engineered EGF-R antibodies mediate improved antibody-dependent cellular cytotoxicity (ADCC) against KRAS-mutated tumor cells
- Complement-mediated tumor-specific cell lysis by antibody combinations targeting epidermal growth factor receptor (EGFR) and its variant III (EGFRvIII)